Clinical Investigations: Acute Ischemic Heart DiseaseChelation therapy for coronary heart disease: An overview of all clinical investigations☆
Section snippets
Methods
Four independent, computerized literature searches were performed, all from earliest possible available data to the end of 1998 (Medline, Embase, Cochrane Library, and CISCOM [a database specialized in complementary/alternative medicine]). The aim was to identify all clinical investigations of chelation therapy for cardiovascular disease. The key words used were chelation, EDTA, ethylenediamine tetraacetic acid, edeteate, edeteate sodium, edetic acid, vascular disease, and controlled clinical
Results
Twenty-two studies8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 without control groups were located (Table I). The majority of these studies were published in the 1960s and report subjective symptomatic improvements in most patients. The 2 case reports that included objective angiographic results25, 26 showed no evidence of benefit.
Only 2 controlled clinical trials were located.17, 30 Kitchell et al17 conducted a placebo-controlled, double-blind, crossover
Discussion
These reports collectively provide no reliable evidence to suggest that chelation therapy is of benefit in CHD. Most of the uncontrolled data imply that chelation has positive effects. These reports are consistent with a powerful placebo effect of chelation treatment. The power of the placebo responses in CHD is perhaps best highlighted by the fact that sham surgery has been shown to yield symptomatic benefit in the vast majority of CHD patients.31 When angiographic verification is sought in
References (37)
Arteriosclerosis, occlusive vascular disease and EDTA
Am J Cardiology
(1960)- et al.
Potential uses of chelation methods in the treatment of cardiovascular diseases
Prog Cardiovasc Dis
(1961) - et al.
The treatment of coronary artery disease with disodium EDTA
Am J Cardiol
(1963) - et al.
Comparison of internal mammary ligation and sham operation for angina pectoris
Am J Cardiol
(1960) Chelation therapy for peripheral arterial occlusive disease
Circulation
(1997)- et al.
Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial
Ann Intern Med
(1999) - et al.
EDTA chelation therapy in the treatment of vascular disease
J Cardiovasc Nurs
(1996) Chelation therapy
- et al.
So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy
Ann Pharmacother
(1993) - et al.
Chelation therapy of atherosclerosis
Drug Int Clin Pharm
(1984)
The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis
J Advancement Med
The “in vivo” dissolution of metastatic calcium: an approach to atherosclerosis
Am J Med Sci
Treatment of angina pectoris with disodium EDTA
Am J Med Sci
Studies in human and induced atherosclerosis employing EDTA
Bull Schw Akad Wiss
Chelation therapy
Treatment of occlusive vascular disease with disodium EDTA
Am J Med Sci
Chelation therapy in circulatory and sclerosing diseases
Fed Proc
The long-term use, side-effects, and toxicity of disodium EDTA
Am J Med Sci
Cited by (72)
Metal ion mediated aggregation of Alzheimer's disease peptides and proteins in solutions and at surfaces
2023, Advances in Colloid and Interface ScienceMetallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives
2021, Journal of Trace Elements in Medicine and BiologyCitation Excerpt :Currently, derived calcium and sodium salts of EDTA - Na2EDTA (disodium EDTA) and CaNa2EDTA (Calcium disodium EDTA) - are being used in clinical medicine. Although they appear to pose a therapeutic potential at first use, studies have revealed that they are hazardous agents in various disease states and are therefore being discontinued or no longer recommended [236,237]. Prolonged treatment with CaNa2EDTA results in depletion of essential metals, especially Zn, Cu, and Mn [238].
The effect of EDTA in combination with some antibiotics against clinical isolates of gram negative bacteria in Mansoura, Egypt
2021, Microbial PathogenesisCitation Excerpt :EDTA has various uses as it acts as a food preservative in a low concentration and present in commercial combination with antibiotics such as Zosyn which is composed of piperacillin/Tazobactam combination [10]. Also it can be combined with minerals and vitamins to treat some diseases such as atherosclerotic vascular disease and renal ischemia [11,12]. EDTA is generally considered as an enhancer of the activity of other antimicrobial agents [13,14].
Differential Outcomes With Edetate Disodium-Based Treatment Among Stable Post Anterior vs. Non-Anterior Myocardial Infarction Patients
2020, Cardiovascular Revascularization MedicineCitation Excerpt :The consistent reduction in most components of the primary endpoint further supports the potential benefit of this therapy. Several potential explanations for the benefit of edetate disodium have been suggested, including the reduction of cardiovascular toxicity from low-level exposure to metals such as lead and cadmium, improvement in endothelial function, and potential improvement in symptoms [26,27]. Epidemiological and basic studies have long supported the hypothesis that both lead and cadmium are ubiquitous and vasculotoxic [28–31].
Clawing back: Broadening the notion of metal chelators in medicine
2013, Current Opinion in Chemical BiologyCitation Excerpt :Subsequent theories promoted by chelation practitioners posit that EDTA removes heavy metals and reduces oxidative stress, regardless of the well-known catalytic activity of Fe-EDTA to generate reactive oxygen species [10]. Research has found no evidence for efficacy of EDTA chelation therapy for cardiovascular disease [11]. The over-hyped promises, lack of reputable proof of efficacy, and scientifically unsound justifications for these non-approved uses of chelating agents have contributed to a negative view of chelation.
Letter to the Editor concerning article Design of the Trial to Assess Chelation Therapy (TACT)
2012, American Heart Journal
- ☆
Reprint requests: E. Ernst, MD, Department of Complementary Medicine, School of Postgraduate Medicine and Health Sciences, University of Exeter, 25 Victoria Park Rd, Exeter EX2 4NT, United Kingdom. E-mail: [email protected]